{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:31Z","timestamp":1786980571572,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Pharmaceutical Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10157-025-02698-5","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:31:22Z","timestamp":1748928682000},"page":"1591-1598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of an educational program for community pharmacists involved in pharmacotherapy for patients with impaired renal function: a preliminary study"],"prefix":"10.1007","volume":"29","author":[{"given":"Akio","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-7721","authenticated-orcid":false,"given":"Yuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2698_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE. 2016;11: e0158765.","journal-title":"PLoS ONE"},{"key":"2698_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","volume":"13","author":"E Imai","year":"2009","unstructured":"Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"2698_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"2698_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease. Clin J Am Soc Nephrol. 2018;13:1085\u201395.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2698_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2215\/CJN.10960917","volume":"13","author":"F Keller","year":"2018","unstructured":"Keller F, Hann A. Clinical pharmacodynamics. Clin J Am Soc Nephrol. 2018;13:1413\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2698_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.18773\/austprescr.2019.054","volume":"42","author":"M Stefani","year":"2019","unstructured":"Stefani M, Singer RF, Roberts DM. How to adjust drug doses in chronic kidney disease. Aust Prescr. 2019;42:163\u20137.","journal-title":"Aust Prescr"},{"key":"2698_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1525-1497.2001.016006369.x","volume":"16","author":"AD Falconnier","year":"2001","unstructured":"Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med. 2001;16:369\u201375.","journal-title":"J Gen Intern Med"},{"key":"2698_CR8","first-page":"304","volume":"37","author":"K Dong","year":"2010","unstructured":"Dong K, Quan DJ. Appropriately assessing renal function for drug dosing. Nephrol Nurs J. 2010;37:304\u20138.","journal-title":"Nephrol Nurs J"},{"key":"2698_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2369-12-35","volume":"12","author":"G Stemer","year":"2011","unstructured":"Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12:35.","journal-title":"BMC Nephrol"},{"key":"2698_CR10","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1345\/aph.1M187","volume":"43","author":"Y Hassan","year":"2009","unstructured":"Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598\u2013605.","journal-title":"Ann Pharmacother"},{"key":"2698_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/phar.1508","volume":"34","author":"KD Barnes","year":"2014","unstructured":"Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Pharmacotherapy. 2014;34:1330\u20135.","journal-title":"Pharmacotherapy"},{"key":"2698_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2296-14-96","volume":"14","author":"MA Via-Sosa","year":"2013","unstructured":"Via-Sosa MA, Lopes N, March M. Effectiveness of a drug dosing service provided by community pharmacists in polymedicated elderly patients with renal impairment\u2013a comparative study. BMC Fam Pract. 2013;14:96.","journal-title":"BMC Fam Pract"},{"key":"2698_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1715163515618421","volume":"149","author":"YN Al Hamarneh","year":"2016","unstructured":"Al Hamarneh YN, Hemmelgarn B, Curtis C, Balint C, Jones CA, Tsuyuki RT. Community pharmacist targeted screening for chronic kidney disease. Can Pharm J (Ott). 2016;149:13\u20137.","journal-title":"Can Pharm J (Ott)"},{"key":"2698_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12913-014-0615-0","volume":"14","author":"Y Kondo","year":"2014","unstructured":"Kondo Y, Ishitsuka Y, Shigemori E, Irikura M, Kadowaki D, Hirata S, et al. Awareness and current implementation of drug dosage adjustment by pharmacists in patients with chronic kidney disease in Japan: a web-based survey. BMC Health Serv Res. 2014;14:615.","journal-title":"BMC Health Serv Res"},{"key":"2698_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5649\/jjphcs.48.59","volume":"48","author":"A Ogino","year":"2022","unstructured":"Ogino A, Kondo Y, Sato K, Sakamaki T, Tominaga Y. Current status and issues regarding pharmaceutical management of patients with impaired renal function in community pharmacies: a nationwide survey. Iryo Yakugaku (Jpn J Pharm Health Care Sci). 2022;48:59\u201369.","journal-title":"Iryo Yakugaku (Jpn J Pharm Health Care Sci)"},{"key":"2698_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.ajkd.2017.05.008","volume":"70","author":"L Lalonde","year":"2017","unstructured":"Lalonde L, Quintana-B\u00e1rcena P, Lord A, Bell R, Cl\u00e9ment V, Daigneault A-M, et al. Community pharmacist training-and-communication network and drug-related problems in patients with CKD: a multicenter, cluster-randomized. Controlled Trial Am J Kidney Dis. 2017;70:386\u201396.","journal-title":"Controlled Trial Am J Kidney Dis"},{"key":"2698_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41100-025-00618-7","volume":"11","author":"Y Kondo","year":"2025","unstructured":"Kondo Y, Shikamura Y, Suzuki M, Takahashi M, Kawakami E, Hashiba H, et al. Renal function ascertainment rate of patients at community pharmacies in Japan: a national survey. Renal Replace Therapy. 2025;11:22.","journal-title":"Renal Replace Therapy"},{"key":"2698_CR18","unstructured":"Dosage recommendations for drugs that require the most attention in renal impairment, 36th edition [Internet]. [cited 2023 Dec 14]. Available from: https:\/\/www.jsnp.org\/docs\/dosage_recommendations_36.pdf"},{"key":"2698_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/chp.20119","volume":"31","author":"M-\u00c8 Legris","year":"2011","unstructured":"Legris M-\u00c8, S\u00e9guin NC, Desforges K, Sauv\u00e9 P, Lord A, Bell R, et al. Pharmacist Web-based training program on medication use in chronic kidney disease patients: impact on knowledge, skills, and satisfaction. J Contin Educ Health Prof. 2011;31:140\u201350.","journal-title":"J Contin Educ Health Prof"},{"key":"2698_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s11096-016-0330-5","volume":"38","author":"PA Gheewala","year":"2016","unstructured":"Gheewala PA, Peterson GM, Zaidi STR, Bereznicki L, Jose MD, Castelino RL. A web-based training program to support chronic kidney disease screening by community pharmacists. Int J Clin Pharm. 2016;38:1080\u20136.","journal-title":"Int J Clin Pharm"},{"key":"2698_CR21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.5649\/jjphcs.41.732","volume":"41","author":"R Eto","year":"2015","unstructured":"Eto R, Amamoto K, Ueshima Y, Yamaguchi K, Doi T, Shimosaka K, et al. Community-pharmacy based trials for drug dose adjustment in which pharmacists evaluate renal function. Iryo Yakugaku (Jpn J Pharm Health Care Sci). 2015;41:732\u20137.","journal-title":"Iryo Yakugaku (Jpn J Pharm Health Care Sci)"},{"key":"2698_CR22","doi-asserted-by":"publisher","first-page":"8701","DOI":"10.21037\/apm-21-817","volume":"10","author":"X-X Liu","year":"2021","unstructured":"Liu X-X, Wang H-X, Hu Y-Y, Zhu X-T, Tan X, Yang Y, et al. Drug-related problems identified by clinical pharmacists in nephrology department of a tertiary hospital in China-a single center study. Ann Palliat Med. 2021;10:8701\u20138.","journal-title":"Ann Palliat Med"},{"key":"2698_CR23","doi-asserted-by":"publisher","first-page":"1504371","DOI":"10.1155\/2019\/1504371","volume":"2019","author":"AW Garedow","year":"2019","unstructured":"Garedow AW, Mulisa Bobasa E, Desalegn Wolide A, Kerga Dibaba F, Gashe Fufa F, Idilu Tufa B, et al. Drug-related problems and associated factors among patients admitted with chronic kidney disease at Jimma University medical center, Jimma Zone, Jimma, Southwest Ethiopia: a hospital-based prospective observational study. Int J Nephrol. 2019;2019:1504371.","journal-title":"Int J Nephrol"},{"key":"2698_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12882-023-03210-5","volume":"24","author":"A Pehlivanli","year":"2023","unstructured":"Pehlivanli A, Eyupoglu S, Basgut B, Erturk S, Ozcelikay AT. Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug related problems in chronic kidney patients: a prospective interventional study. BMC Nephrol. 2023;24:149.","journal-title":"BMC Nephrol"},{"key":"2698_CR25","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1097\/TA.0b013e318267cd80","volume":"73","author":"S Hamblin","year":"2012","unstructured":"Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484\u201390.","journal-title":"J Trauma Acute Care Surg"},{"key":"2698_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1525-139x.2002.00014.x","volume":"15","author":"HJ Manley","year":"2002","unstructured":"Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial. 2002;15:45\u20139.","journal-title":"Semin Dial"},{"key":"2698_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1248\/yakushi.132.753","volume":"132","author":"Y Shikamura","year":"2012","unstructured":"Shikamura Y, Oyama A, Takahashi J, Akagi Y, Negishi K, Ijyuin K, et al. Medical economics research on awareness of community pharmacists about raising pharmaceutical questions regarding prescriptions issued by physicians. Yakugaku Zasshi. 2012;132:753\u201361.","journal-title":"Yakugaku Zasshi"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02698-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:33:47Z","timestamp":1761708827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02698-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02698-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported by a research grant received from the Japan Pharmaceutical Association. YI reports having patents or royalties with the Safety Medical System Laboratory Corporation. YK reports receiving research funding from Safety Medical System Laboratory Corporation; having patents or royalties with Safety Medical System Laboratory Corporation; and serving in an advisory or leadership role for Safety Medical System Laboratory Corporation (unpaid). The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 2489) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}